Related Experiment Video
Updated: Aug 7, 2026

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
Published on: August 16, 2016
Neurally mediated cardiac effects of forskolin in conscious dogs
M Iwase1, Y Ishikawa, Y T Shen
1Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston 02115, USA.
Abstract:
Because major cardiovascular disease states are characterized by defects in adenylyl cyclase regulation, it becomes important to understand the mechanisms by which adenylyl cyclase activators affect inotropy and chronotropy in intact conscious animals. Accordingly, we examined the inotropic and chronotropic responses to forskolin in 11 normal conscious, chronically instrumented dogs and 3 dogs with ventricular denervation (VD). Left ventricular first derivative of pressure (LV dP/dt) increased by 96 +/- 7%, P < 0.05, in response to forskolin (50 nmol.kg-1.min-1) in normal dogs and by significantly less, 52 +/- 14%, in VD dogs. Circulating norepinephrine (NE) levels increased similarly in both groups (from 226 +/- 18 to 389 +/- 33 pg/ml in normal dogs, from 177 +/- 23 to 329 +/- 71 pg/ml in VD dogs). In the presence of ganglionic blockade, the increase in LV dP/dt in response to forskolin was reduced (+62 +/- 4%) in normal dogs but was unchanged in VD dogs (+52 +/- 12%). Ganglionic blockade abolished the increase in circulating NE levels in both groups. Increases in heart rate in the presence of ganglionic blockade (+54 +/- 6 beats/min) were less than in the presence of atropine alone (+92 +/- 10 beats/min). Notably, the LV dP/dt and heart rate responses to forskolin were further attenuated by beta-adrenergic receptor blockade in the presence and absence of ganglionic blockade. Morphine also attenuated the increases in both LV dP/dt and plasma NE in response to forskolin. Increases in LV dP/dt in response to NKH-477 (30 micrograms/kg), a water-soluble forskolin derivative, were similar before and after ganglionic blockade (+63 +/- 8 and +51 +/- 10%, respectively). However, in vitro experiments in LV sarcolemmal membrane preparations demonstrated that stimulation of adenylyl cyclase by forskolin and NKH-477 was not affected by beta-adrenergic receptor blockade. These results indicate that in conscious dogs, inotropic and chronotropic effects of forskolin are not only due to direct activation of adenylyl cyclase, but the effects also are mediated by neural mechanisms and potentiated by the prevailing level of sympathetic tone.
Insights
Forskolin enhances heart function through direct adenylyl cyclase activation and neural pathways. These effects are modulated by sympathetic tone and blocked by beta-adrenergic receptors in conscious dogs.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
Background:
- Cardiovascular diseases involve adenylyl cyclase regulation defects.
- Understanding adenylyl cyclase activators' effects on heart function is crucial.
Purpose of the Study:
- To investigate the inotropic and chronotropic effects of forskolin in conscious dogs.
- To elucidate the role of neural mechanisms and sympathetic tone in forskolin's actions.
Main Methods:
- Administered forskolin and NKH-477 to normal and ventricular denervated dogs.
- Utilized ganglionic blockade, atropine, and beta-adrenergic blockade.
- Measured left ventricular pressure derivative (LV dP/dt) and norepinephrine levels.
Main Results:
- Forskolin increased LV dP/dt and heart rate, with attenuated effects in denervated dogs and after ganglionic blockade.
- Beta-adrenergic blockade and morphine further reduced forskolin's effects.
- In vitro studies showed direct adenylyl cyclase activation unaffected by beta-blockade.
Conclusions:
- Forskolin's inotropic and chronotropic effects in conscious dogs involve both direct adenylyl cyclase activation and neural mechanisms.
- Sympathetic tone potentiates forskolin's cardiac effects.
- Neural pathways and sympathetic tone significantly contribute to forskolin's cardiovascular actions.
Related Concept Videos
Pathophysiology of Cardiac Performance
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

